Comments
Torrent Pharmaceuticals Limited on Wednesday posted consolidated net profit of ₹283 crore for the quarter ended December 2022, up 14 per cent from ₹249 crore in the corresponding quarter last year.
Company’s consolidated revenues from operations stood at ₹2,491 crore, up 18 per cent from ₹2,108 crore in the same quarter last year.
The company attributed the revenue growth to branded markets. The consolidated EBITDA grew by 35 pre cent to ₹724 crore for the quarter under review.
For the nine-month period, the company posted net profit of ₹949 crore, up 6 per cent from ₹895 crore in the same period last year. Revenue from operations stood at ₹7,129 crore, up 12 per cent from ₹6,379 crore in the same period last year.
On standalone basis, company’s net profit for the quarter stood at ₹229 crore, up from ₹170 crore in the same quarter last year. Standalone revenue from operations stood at ₹1,857 crore, up from ₹1,588 crore in the corresponding quarter last year.
India revenues stood at ₹1,259 crore, up 17 per cent year-on-year, while its Brazil revenues increased 36 per cent to ₹248 crore. Its Germany revenues remained nearly flat at ₹241 crore, up 1 per cent, while US revenues grew by 24 per cent to ₹291 crore for the quarter under review.
Torrent Pharmaceuticals shares slipped 1.86 per cent to end at ₹1557.50 on the BSE Wednesday.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.